Facebook Live 4/29- Answers

Looking at the Washington state data, we are past the spike of our curve. As a result, we have reached a much lower peak than we thought, it is about 25% less than we initially thought.


I’m going to go over and go through the Governor’s plans to head back to work, and I’m going to try and clarify some things there.


Looking at the UVA data, the southwest region has had much less of a hit than more urban areas like northern Virginia, and greater Richmond.


One final update on the convalescent plasma and the nurse at VCU, he did receive the plasma he needed, and he is on the path to recovery. If you think you could potentially be a plasma donor, please go to my website and see if you fit the Red Cross criteria and if you can help out.


Question 1:

If hospitalizations are going to be a metric for reopening, what happens when the directive to test everyone going to the hospital for any reason increases the number of positive patients?

Answer:

We are not looking at the tests done and the tests positive, we are looking at the percent of tests that are positive, because that is a number we can get a denominator on. If we test a larger number of people, those who don’t even have symptoms, there will be a gradually lower percentage of those tested will come back positive. The metric used will be percent positive, and that’s how we will see the curve change.


Question 2:

We hear that some tests have a high percentages of specificity in testing, what are we going to do about that?

Answer: The FDA has not approved any of these tests yet. There are emergency use tests that are allowable, and those tests are used to run a trial to gauge the specificity and sensitivity, and then that information is sent to the FDA to see if that is usable for emergencies. We have one of those tests in our area. 9,000 people in Henrico who had proven to be positive were tested, and those were found to have a 99% specificity and sensitivity response. That test is being used in the greater Richmond area at BetterMed, but the problem is that it is not technically FDA approved. We are still working on reliable tests.


Question 3:

How do we use this data? How does this change the course of what we’re doing?

Answer:

Right now, it’s more scientific. We are trying to test and see how many people have had this. But there isn’t a wa